Toll-like receptor agonists as cancer vaccine adjuvants

References

• Esfahani K, Roudaia L, Buhlaiga N, Del Rincon SV, Papneja N, Miller WH. A review of cancer immunotherapy: from the past, to the present, to the future. Curr Oncol. 2020;27(12):87–18. doi:10.3747/co.27.5223.
   Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411–22. doi:10.1056/NEJMoa1001294.
   PubMed Web of Science ®Google Scholar
• Nakamura K, Smyth MJ. Myeloid immunosuppression and immune checkpoints in the tumor microenvironment. Cell Mol Immunol. 2020;17(1):1–12. doi:10.1038/s41423-019-0306-1.
   PubMed Web of Science ®Google Scholar
• Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol. 2007;25(1):267–96. doi:10.1146/annurev.immunol.25.022106.141609.
   PubMed Web of Science ®Google Scholar
• Gajewski TF, Meng Y, Blank C, Brown I, Kacha A, Kline J, Harlin H. Immune resistance orchestrated by the tumor microenvironment. Immunol Rev. 2006;213:131–45. doi:10.1111/j.1600-065X.2006.00442.x.
   PubMed Web of Science ®Google Scholar
• Puig-Saus C, Sennino B, Peng S, Wang CL, Pan Z, Yuen B, Purandare B, An D, Quach BB, Nguyen D, et al. Neoantigen-targeted CD8+ T cell responses with PD-1 blockade therapy. Nature. 2023;615(7953):697–704. doi:10.1038/s41586-023-05787-1.
   PubMed Web of Science ®Google Scholar
• Bobisse S, Foukas PG, Coukos G, Harari A. Neoantigen-based cancer immunotherapy. Ann Transl Med. 2016;4(14):262. doi:10.21037/atm.2016.06.17.
   PubMed Web of Science ®Google Scholar
• Zahm CD, Colluru VT, McNeel DG. Vaccination with high-affinity epitopes impairs antitumor efficacy by increasing PD-1 expression on CD8(+) T cells. Cancer Immunol Res. 2017;5(8):630–41. doi:10.1158/2326-6066.CIR-16-0374.
   PubMed Web of Science ®Google Scholar
• Rekoske BT, Olson BM, McNeel DG. Antitumor vaccination of prostate cancer patients elicits PD-1/PD-L1 regulated antigen-specific immune responses. Oncoimmunology. 2016;5(6):e1165377. doi:10.1080/2162402X.2016.1165377.
   PubMed Web of Science ®Google Scholar
• McNeel DG, Eickhoff JC, Wargowski E, Zahm C, Staab MJ, Straus J, Liu G. Concurrent, but not sequential, PD-1 blockade with a DNA vaccine elicits anti-tumor responses in patients with metastatic, castration-resistant prostate cancer. Oncotarget. 2018;9(39):25586–96. doi:10.18632/oncotarget.25387.
   PubMedGoogle Scholar
• McNeel DG, Eickhoff JC, Wargowski E, Johnson LE, Kyriakopoulos CE, Emamekhoo H, Lang JM, Brennan MJ, Liu G. Phase 2 trial of T-cell activation using MVI-816 and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC). J Immunother Cancer. 2022;10(3):10. doi:10.1136/jitc-2021-004198.
   Web of Science ®Google Scholar
• Carvalho T. Personalized anti-cancer vaccine combining mRNA and immunotherapy tested in melanoma trial. Nat Med. 2023;29:2379–80.
   Google Scholar
• Iclozan C, Antonia S, Chiappori A, Chen DT, Gabrilovich D. Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer. Cancer Immunol Immunother. 2013;62(5):909–18. doi:10.1007/s00262-013-1396-8.
   PubMed Web of Science ®Google Scholar
• Brezar V, Godot V, Cheng L, Su L, Lévy Y, Seddiki N. T-Regulatory cells and vaccination “pay attention and do not neglect them”: lessons from HIV and cancer vaccine trials. Vaccines (Basel). 2016;4(3):30. doi:10.3390/vaccines4030030.
   PubMed Web of Science ®Google Scholar
• Llopiz D, Ruiz M, Silva L, Sarobe P. Enhancement of antitumor vaccination by targeting dendritic cell-related IL-10. Front Immunol. 2018;9. doi:10.3389/fimmu.2018.01923.
   PubMed Web of Science ®Google Scholar
• Marciani DJ. Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity. Drug Discov Today. 2003;8(20):934–43. doi:10.1016/S1359-6446(03)02864-2.
   PubMed Web of Science ®Google Scholar
• Dubensky TW, Reed SG. Adjuvants for cancer vaccines. Semin Immunol. 2010;22(3):155–61. doi:10.1016/j.smim.2010.04.007.
   PubMed Web of Science ®Google Scholar
• Zindel J, Kubes P. DAMPs, PAMPs , and LAMPs in immunity and sterile inflammation. Annu Rev Pathol. 2020;15(1):493–518. doi:10.1146/annurev-pathmechdis-012419-032847.
   PubMedGoogle Scholar
• Srikrishna G, Freeze HH. Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer. Neoplasia. 2009;11(7):615–28. doi:10.1593/neo.09284.
   PubMed Web of Science ®Google Scholar
• Janeway CA Jr. The immune system evolved to discriminate infectious nonself from noninfectious self. Immunol Today. 1992;13(1):11–6. doi:10.1016/0167-5699(92)90198-G.
   PubMedGoogle Scholar
• Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity. 2011;34(5):637–50. doi:10.1016/j.immuni.2011.05.006.
   PubMed Web of Science ®Google Scholar
• O’Neill LAJ, Golenbock D, Bowie AG. The history of toll-like receptors — redefining innate immunity. Nat Rev Immunol. 2013;13(6):453–60. doi:10.1038/nri3446.
   PubMed Web of Science ®Google Scholar
• Rock FL, Hardiman G, Timans JC, Kastelein RA, Bazan JF. A family of human receptors structurally related to drosophila Toll. Proc Natl Acad Sci. 1998;95(2):588–93. doi:10.1073/pnas.95.2.588.
   PubMed Web of Science ®Google Scholar
• Takeda K, Akira S. Toll-like receptors. Curr Protoc Immunol. 2015;109(1): 14.2.1–.2.0. doi:10.1002/0471142735.im1412s109.
   PubMedGoogle Scholar
• Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol. 2003;21(1):335–76. doi:10.1146/annurev.immunol.21.120601.141126.
   PubMed Web of Science ®Google Scholar
• Tomai MA, Vasilakos JP. TLR agonists as vaccine adjuvants. In: Baschieri S, editor. Innovation in vaccinology: from design, through to delivery and testing. Dordrecht: Springer; 2012. pp. 205–28.
   Google Scholar
• Lou Y, Liu C, Lizée G, Peng W, Xu C, Ye Y, Rabinovich BA, Hailemichael Y, Gelbard A, Zhou D. et al. Antitumor activity mediated by CpG: the route of administration is critical. J Immunother. 2011;34(3):279–88. doi:10.1097/CJI.0b013e31820d2a05.
   PubMed Web of Science ®Google Scholar
• Gableh F, Saeidi M, Hemati S, Hamdi K, Soleimanjahi H, Gorji A, Ghaemi A. Combination of the toll like receptor agonist and α-galactosylceramide as an efficient adjuvant for cancer vaccine. J Biomed Sci. 2016;23(1):16. doi:10.1186/s12929-016-0238-3.
   PubMedGoogle Scholar
• Sajadian A, Tabarraei A, Soleimanjahi H, Fotouhi F, Gorji A, Ghaemi A. Comparing the effect of toll-like receptor agonist adjuvants on the efficiency of a DNA vaccine. Arch Virol. 2014;159(8):1951–60. doi:10.1007/s00705-014-2024-4.
   PubMed Web of Science ®Google Scholar
• Domingos-Pereira S, Decrausaz L, Derré L, Bobst M, Romero P, Schiller JT, Jichlinski P, Nardelli-Haefliger D. Intravaginal TLR agonists increase local vaccine-specific CD8 T cells and human papillomavirus-associated genital-tumor regression in mice. Mucosal Immunol. 2013;6(2):393–404. doi:10.1038/mi.2012.83.
   PubMed Web of Science ®Google Scholar
• Dunne A, Marshall NA, Mills KH. TLR based therapeutics. Curr Opin Pharmacol. 2011;11(4):404–11. doi:10.1016/j.coph.2011.03.004.
   PubMed Web of Science ®Google Scholar
• Yang Y, Li H, Fotopoulou C, Cunnea P, Zhao X. Toll-like receptor-targeted anti-tumor therapies: advances and challenges. Front Immunol. 2022;13:1049340. doi:10.3389/fimmu.2022.1049340.
   PubMedGoogle Scholar
• Flo TH, Halaas O, Torp S, Ryan L, Lien E, Dybdahl B, Sundan A, Espevik T. Differential expression of toll-like receptor 2 in human cells. J Leukoc Biol. 2001;69(3):474–81. doi:10.1189/jlb.69.3.474.
   PubMed Web of Science ®Google Scholar
• Brzezińska-Błaszczyk E, Wierzbicki M. Mast cell toll-like receptors (TLRs). Postepy Hig Med Dosw (Online). 2010;64:11–21.
   PubMedGoogle Scholar
• Farhat K, Riekenberg S, Heine H, Debarry J, Lang R, Mages J, Buwitt-Beckmann U, Röschmann K, Jung G, Wiesmüller K-H. et al. Heterodimerization of TLR2 with TLR1 or TLR6 expands the ligand spectrum but does not lead to differential signaling. J Leukoc Biol. 2007;83(3):692–701. doi:10.1189/jlb.0807586.
   PubMed Web of Science ®Google Scholar
• de Oliviera Nascimento L, Massari P, Wetzler L. The role of TLR2 in infection and immunity. Front Immunol. 2012;3:3. doi:10.3389/fimmu.2012.00079.
   PubMed Web of Science ®Google Scholar
• Beutler B, Jiang Z, Georgel P, Crozat K, Croker B, Rutschmann S, Du X, Hoebe K. Genetic analysis of host resistance: toll-like receptor signaling and immunity at large. Annu Rev Immunol. 2006;24(1):353–89. doi:10.1146/annurev.immunol.24.021605.090552.
   PubMedGoogle Scholar
• Xu Y, Tao X, Shen B, Horng T, Medzhitov R, Manley JL, Tong L. Structural basis for signal transduction by the toll/interleukin-1 receptor domains. Nature. 2000;408(6808):111–15. doi:10.1038/35040600.
   PubMed Web of Science ®Google Scholar
• Won K, Kim SM, Lee SA, Rhim BY, Eo SK, Kim K. Multiple signaling molecules are involved in expression of CCL2 and IL-1β in response to FSL-1, a toll-like receptor 6 agonist, in macrophages. Korean J Physiol Pharmacol. 2012;16(6):447–53. doi:10.4196/kjpp.2012.16.6.447.
   PubMed Web of Science ®Google Scholar
• De Buck M, Berghmans N, Pörtner N, Vanbrabant L, Cockx M, Struyf S, Opdenakker G, Proost P, Van Damme J, Gouwy M. et al. Serum amyloid A1α induces paracrine IL-8/CXCL8 via TLR2 and directly synergizes with this chemokine via CXCR2 and formyl peptide receptor 2 to recruit neutrophils. J Leukoc Biol. 2015;98(6):1049–60. doi:10.1189/jlb.3A0315-085R.
   PubMed Web of Science ®Google Scholar
• Need AC, Goldstein DB. Next generation disparities in human genomics: concerns and remedies. Trends Genet. 2009;25(11):489–94. doi:10.1016/j.tig.2009.09.012.
   PubMed Web of Science ®Google Scholar
• Chang YL, Chen TH, Wu YH, Chen GA, Weng TH, Tseng PH, Hsieh SL, Fu SL, Lin CH, Chen CJt et al. A novel TLR2-triggered signalling crosstalk synergistically intensifies TNF-mediated IL-6 induction. J Cell Mol Med. 2014;18(7):1344–57. doi:10.1111/jcmm.12294.
   PubMed Web of Science ®Google Scholar
• Flynn CM, Garbers Y, Lokau J, Wesch D, Schulte DM, Laudes M, Lieb W, Aparicio-Siegmund S, Garbers C. Activation of toll-like receptor 2 (TLR2) induces interleukin-6 trans-signaling. Sci Rep. 2019;9(1):7306. doi:10.1038/s41598-019-43617-5.
   PubMed Web of Science ®Google Scholar
• Kaur A, Kaushik D, Piplani S, Mehta SK, Petrovsky N, Salunke DB. TLR2 agonistic small molecules: detailed structure–activity relationship, applications, and future prospects. J Med Chem. 2021;64(1):233–78. doi:10.1021/acs.jmedchem.0c01627.
   PubMed Web of Science ®Google Scholar
• Knapp S, von Aulock S, Leendertse M, Haslinger I, Draing C, Golenbock DT, van der Poll T. Lipoteichoic acid-induced lung inflammation depends on TLR2 and the concerted action of TLR4 and the platelet-activating factor receptor. J Immunol. 2008;180(5):3478–84. doi:10.4049/jimmunol.180.5.3478.
   PubMed Web of Science ®Google Scholar
• Müller-Anstett MA, Müller P, Albrecht T, Nega M, Wagener J, Gao Q, Kaesler S, Schaller M, Biedermann T, Götz Fp et al. Staphylococcal peptidoglycan co-localizes with Nod2 and TLR2 and activates innate immune response via both receptors in primary murine keratinocytes. PLOS ONE. 2010;5(10):e13153. doi:10.1371/journal.pone.0013153.
   PubMed Web of Science ®Google Scholar
• Frasnelli ME, Tarussio D, Chobaz-Péclat V, Busso N, So A. TLR2 modulates inflammation in zymosan-induced arthritis in mice. Arthritis Res Ther. 2005;7(2):R370. doi:10.1186/ar1494.
   PubMed Web of Science ®Google Scholar
• Campos MAS, Almeida IC, Takeuchi O, Akira S, Valente EP, Procópio DO, Travassos LR, Smith JA, Golenbock DT, Gazzinelli RT, et al. Activation of toll-like receptor-2 by Glycosylphosphatidylinositol anchors from a protozoan Parasite1. J Immunol. 2001;167(1):416–23. doi:10.4049/jimmunol.167.1.416.
   PubMed Web of Science ®Google Scholar
• Tapping RI, Tobias PS. Mycobacterial lipoarabinomannan mediates physical interactions between TLR1 and TLR2 to induce signaling. J Endotoxin Res. 2003;9(4):264–8. doi:10.1177/09680519030090040801.
   PubMedGoogle Scholar
• Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-κB by toll-like receptor 3. Nature. 2001;413(6857):732–8. doi:10.1038/35099560.
   PubMed Web of Science ®Google Scholar
• Kadowaki N, Ho S, Antonenko S, Malefyt RW, Kastelein RA, Bazan F, Liu Y-J. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med. 2001;194(6):863–9. doi:10.1084/jem.194.6.863.
   PubMed Web of Science ®Google Scholar
• Tabiasco J, Devêvre E, Rufer N, Salaun B, Cerottini JC, Speiser D, Romero P. Human effector CD8+ T lymphocytes express TLR3 as a functional coreceptor. J Immunol. 2006;177(12):8708–13. doi:10.4049/jimmunol.177.12.8708.
   PubMed Web of Science ®Google Scholar
• Schmidt KN, Leung B, Kwong M, Zarember KA, Satyal S, Navas TA, Wang F, Godowski PJ. APC-independent activation of NK cells by the Toll-like receptor 3 agonist double-stranded RNA. J Immunol. 2004;172(1):138–43. doi:10.4049/jimmunol.172.1.138.
   PubMed Web of Science ®Google Scholar
• Cario E, Podolsky DK, Clements JD. Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun. 2000;68(12):7010–7. doi:10.1128/IAI.68.12.7010-7017.2000.
   PubMed Web of Science ®Google Scholar
• Fang F, Ooka K, Sun X, Shah R, Bhattacharyya S, Wei J, Varga J. A synthetic TLR3 ligand mitigates profibrotic fibroblast responses by inducing autocrine IFN signaling. J Immunol. 2013;191(6):2956–66. doi:10.4049/jimmunol.1300376.
   PubMed Web of Science ®Google Scholar
• Matsumoto M, Funami K, Tanabe M, Oshiumi H, Shingai M, Seto Y, Yamamoto A, Seya T. Subcellular localization of Toll-like receptor 3 in human dendritic cells. J Immunol. 2003;171(6):3154–62. doi:10.4049/jimmunol.171.6.3154.
   PubMed Web of Science ®Google Scholar
• Jiang Z, Mak TW, Sen G, Li X. Toll-like receptor 3-mediated activation of NF-κB and IRF3 diverges at toll-IL-1 receptor domain-containing adapter inducing IFN-β. Proc Natl Acad Sci USA. 2004;101(10):3533–8. doi:10.1073/pnas.0308496101.
   PubMed Web of Science ®Google Scholar
• Schulz O, Diebold SS, Chen M, Näslund TI, Nolte MA, Alexopoulou L, Azuma YT, Flavell RA, Liljeström P, Reis e Sousa C. et al. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature. 2005;433(7028):887–92. doi:10.1038/nature03326.
   PubMed Web of Science ®Google Scholar
• Lebre MC, Antons JC, Kalinski P, Schuitemaker JH, van Capel TM, Kapsenberg ML, de Jong EC. Double-stranded RNA-Exposed human keratinocytes promote Th1 responses by inducing a type-1 Polarized Phenotype in dendritic cells: role of Keratinocyte-derived tumor Necrosis factor α, type I interferons, and interleukin-18. J Invest Dermatol. 2003;120(6):990–7. doi:10.1046/j.1523-1747.2003.12245.x.
   PubMed Web of Science ®Google Scholar
• Jiang Z, Zamanian-Daryoush M, Nie H, Silva AM, Williams BR, Li X. Poly(dI·dC)-induced toll-like receptor 3 (TLR3)-mediated activation of NFκB and MAP kinase is through an Interleukin-1 receptor-associated kinase (IRAK)-independent pathway employing the signaling components TLR3-TRAF6-TAK1-TAB2-PKR. J Biol Chem. 2003;278(19):16713–19. doi:10.1074/jbc.M300562200.
   PubMed Web of Science ®Google Scholar
• Padalko E, Nuyens D, De Palma A, Verbeken E, Aerts JL, De Clercq E, Carmeliet P, Neyts J. The interferon inducer ampligen [poly(I)-poly(C12U)] markedly protects mice against coxsackie B3 virus-induced myocarditis. Antimicrob Agents Chemother. 2004;48(1):267–74. doi:10.1128/AAC.48.1.267-274.2004.
   PubMed Web of Science ®Google Scholar
• Levy HB, Baer G, Baron S, Buckler CE, Gibbs CJ, Iadarola MJ, London WT, Rice J. A modified polyriboinosinic-polyribocytidylic acid complex that induces interferon in primates. J Infect Dis. 1975;132(4):434–9. doi:10.1093/infdis/132.4.434.
   PubMed Web of Science ®Google Scholar
• Levy HB, Riley FL, Lvovsky E, Stephen EE. Interferon induction in primates by stabilized polyriboinosinic acid-polyribocytidylic acid: effect of component size. Infect Immun. 1981;34(2):416–21. doi:10.1128/iai.34.2.416-421.1981.
   PubMed Web of Science ®Google Scholar
• Matsumoto M, Tatematsu M, Nishikawa F, Azuma M, Ishii N, Morii-Sakai A, Shime H, Seya T. Defined TLR3-specific adjuvant that induces NK and CTL activation without significant cytokine production in vivo. Nat Commun. 2015;6(1):6280. doi:10.1038/ncomms7280.
   PubMed Web of Science ®Google Scholar
• Jelinek I, Leonard JN, Price GE, Brown KN, Meyer-Manlapat A, Goldsmith PK, Wang Y, Venzon D, Epstein SL, Segal DM. et al. TLR3-Specific double-stranded RNA Oligonucleotide adjuvants induce dendritic cell cross-presentation, CTL responses, and antiviral protection. J Immunol. 2011;186(4):2422–9. doi:10.4049/jimmunol.1002845.
   PubMed Web of Science ®Google Scholar
• Conte MR, Conn GL, Brown T, Lane AN. Conformational properties and thermodynamics of the RNA duplex r(CGCAAAUUUGCG) 2: comparison with the DNA analogue d(CGCAAATTTGCG) 2. Nucleic Acids Res. 1997;25(13):2627–34. doi:10.1093/nar/25.13.2627.
   PubMed Web of Science ®Google Scholar
• Elmén J, Thonberg H, Ljungberg K, Frieden M, Westergaard M, Xu Y, Wahren B, Liang Z, Ørum H, Koch T. et al, Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res. 2005;33(1):439–47. doi:10.1093/nar/gki193.
   PubMed Web of Science ®Google Scholar
• Shetab Boushehri MA, Lamprecht A. TLR4-based Immunotherapeutics in cancer: a review of the achievements and shortcomings. Mol Pharm. 2018;15(11):4777–800. doi:10.1021/acs.molpharmaceut.8b00691.
   PubMed Web of Science ®Google Scholar
• Andreasen AS, Krabbe KS, Krogh-Madsen R, Taudorf S, Pedersen BK, Møller K. Human endotoxemia as a model of systemic inflammation. Curr Med Chem. 2008;15(17):1697–705. doi:10.2174/092986708784872393.
   PubMed Web of Science ®Google Scholar
• Lu YC, Yeh WC, Ohashi PS. LPS/TLR4 signal transduction pathway. Cytokine. 2008;42(2):145–51. doi:10.1016/j.cyto.2008.01.006.
   PubMed Web of Science ®Google Scholar
• Pereira M, Durso DF, Bryant CE, Kurt-Jones EA, Silverman N, Golenbock DT, Gazzinelli RT. The IRAK4 scaffold integrates TLR4-driven TRIF and MYD88 signaling pathways. Cell Rep. 2022;40(7):111225. doi:10.1016/j.celrep.2022.111225.
   PubMed Web of Science ®Google Scholar
• Ling GS, Bennett J, Woollard KJ, Szajna M, Fossati-Jimack L, Taylor PR, Scott D, Franzoso G, Cook HT, Botto M. et al. Integrin CD11b positively regulates TLR4-induced signalling pathways in dendritic cells but not in macrophages. Nat Commun. 2014;5(1):3039. doi:10.1038/ncomms4039.
   PubMedGoogle Scholar
• Jang DI, Lee AH, Shin HY, Song HR, Park JH, Kang TB, Lee SR, Yang SH. The role of tumor necrosis factor alpha (TNF-α) in Autoimmune disease and current TNF-α inhibitors in therapeutics. Int J Mol Sci. 2021;22(5):22. doi:10.3390/ijms22052719.
   Web of Science ®Google Scholar
• Raetz CRH, Whitfield C. Lipopolysaccharide Endotoxins. Annu Rev Biochem. 2002;71(1):635–700. doi:10.1146/annurev.biochem.71.110601.135414.
   PubMedGoogle Scholar
• Miyake K. Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors. Semin Immunol. 2007;19(1):3–10. doi:10.1016/j.smim.2006.12.002.
   PubMed Web of Science ®Google Scholar
• Shimazu R, Akashi S, Ogata H, Nagai Y, Fukudome K, Miyake K, Kimoto M. MD-2, a molecule that confers lipopolysaccharide responsiveness on toll-like receptor 4. J Exp Med. 1999;189(11):1777–82. doi:10.1084/jem.189.11.1777.
   PubMed Web of Science ®Google Scholar
• Schülke S, Flaczyk A, Vogel L, Gaudenzio N, Angers I, Löschner B, Wolfheimer S, Spreitzer I, Qureshi S, Tsai M. et al. MPLA shows attenuated pro-inflammatory properties and diminished capacity to activate mast cells in comparison with LPS. Allergy. 2015;70(10):1259–68. doi:10.1111/all.12675.
   PubMed Web of Science ®Google Scholar
• Arias MA, Van Roey GA, Tregoning JS, Moutaftsi M, Coler RN, Windish HP, Reed SG, Carter D, Shattock RJ. Glucopyranosyl lipid adjuvant (GLA), a synthetic TLR4 Agonist, promotes potent systemic and mucosal responses to intranasal immunization with HIVgp140. PLoS ONE. 2012;7(7):e41144. doi:10.1371/journal.pone.0041144.
   PubMed Web of Science ®Google Scholar
• Kuramitsu Y, Nishibe M, Ohiro Y, Matsushita K, Yuan L, Obara M, Kobayashi M, Hosokawa M. A new synthetic lipid a analog, ONO-4007, stimulates the production of tumor necrosis factor-α in tumor tissues, resulting in the rejection of transplanted rat hepatoma cells. Anticancer Drugs. 1997;8(5):500–8. doi:10.1097/00001813-199706000-00013.
   PubMed Web of Science ®Google Scholar
• Hayashi F, Smith KD, Ozinsky A, Hawn TR, Yi EC, Goodlett DR, Eng JK, Akira S, Underhill DM, Aderem A. et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature. 2001;410(6832):1099–103. doi:10.1038/35074106.
   PubMed Web of Science ®Google Scholar
• Yu S, Gao N. Compartmentalizing intestinal epithelial cell toll-like receptors for immune surveillance. Cell Mol Life Sci. 2015;72(17):3343–53. doi:10.1007/s00018-015-1931-1.
   PubMed Web of Science ®Google Scholar
• Hamonic G, Pasternak JA, Wilson HL. Recognizing conserved non-canonical localization patterns of toll-like receptors in tissues and across species. Cell Tissue Res. 2018;372(1):1–11. doi:10.1007/s00441-017-2767-9.
   PubMed Web of Science ®Google Scholar
• Fitzgerald KA, Kagan JC. Toll-like receptors and the control of immunity. Cell. 2020;180(6):1044–66. doi:10.1016/j.cell.2020.02.041.
   PubMed Web of Science ®Google Scholar
• McDermott PF, Ciacci-Woolwine F, Snipes JA, Mizel SB, Moore RN. High-affinity interaction between gram-negative flagellin and a cell surface polypeptide results in human monocyte activation. Infect Immun. 2000;68(10):5525–9. doi:10.1128/IAI.68.10.5525-5529.2000.
   PubMed Web of Science ®Google Scholar
• Means TK, Hayashi F, Smith KD, Aderem A, Luster AD. The Toll-like receptor 5 stimulus bacterial flagellin induces maturation and chemokine production in human dendritic cells. J Immunol. 2003;170(10):5165–75. doi:10.4049/jimmunol.170.10.5165.
   PubMed Web of Science ®Google Scholar
• Cui B, Liu X, Fang Y, Zhou P, Zhang Y, Wang Y. Flagellin as a vaccine adjuvant. Expert Rev Vaccines. 2018;17(4):335–49. doi:10.1080/14760584.2018.1457443.
   PubMed Web of Science ®Google Scholar
• Rhee JH, Khim K, Puth S, Choi Y, Lee SE. Deimmunization of flagellin adjuvant for clinical application. Curr Opin Virol. 2023;60:101330. doi:10.1016/j.coviro.2023.101330.
   PubMed Web of Science ®Google Scholar
• Zinsli LV, Stierlin N, Loessner MJ, Schmelcher M. Deimmunization of protein therapeutics – recent advances in experimental and computational epitope prediction and deletion. Comput Struct Biotechnol J. 2021;19:315–29. doi:10.1016/j.csbj.2020.12.024.
   PubMed Web of Science ®Google Scholar
• S-I Y, Kurnasov O, Natarajan V, Hong M, Gudkov AV, Osterman AL, Wilson IA. Structural basis of TLR5-flagellin recognition and signaling. Sci. 2012;335(6070):859–64. doi:10.1126/science.1215584.
   PubMed Web of Science ®Google Scholar
• Smith KD, Andersen-Nissen E, Hayashi F, Strobe K, Bergman MA, Barrett SL, Cookson BT, Aderem A. Toll-like receptor 5 recognizes a conserved site on flagellin required for protofilament formation and bacterial motility. Nat Immunol. 2003;4(12):1247–53. doi:10.1038/ni1011.
   PubMed Web of Science ®Google Scholar
• Khim K, Bang YJ, Puth S, Choi Y, Lee YS, Jeong K, Lee SE, Rhee JH. Deimmunization of flagellin for repeated administration as a vaccine adjuvant. NPJ Vaccines. 2021;6(1):116. doi:10.1038/s41541-021-00379-4.
   PubMed Web of Science ®Google Scholar
• Du X, Poltorak A, Wei Y, Beutler B. Three novel mammalian toll-like receptors: gene structure, expression, and evolution. Eur Cytokine Netw. 2000;11:362–71.
   PubMed Web of Science ®Google Scholar
• Lee J, Chuang TH, Redecke V, She L, Pitha PM, Carson DA, Raz E, Cottam HB. Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of Toll-like receptor 7. Proc Natl Acad Sci. 2003;100(11):6646–51. doi:10.1073/pnas.0631696100.
   PubMed Web of Science ®Google Scholar
• Cervantes JL, Weinerman B, Basole C, Salazar JC. TLR8: the forgotten relative revindicated. Cell Mol Immunol. 2012;9(6):434–8. doi:10.1038/cmi.2012.38.
   PubMed Web of Science ®Google Scholar
• Vasilakos JP, Tomai MA. The use of Toll-like receptor 7/8 agonists as vaccine adjuvants. Expert Rev Vaccines. 2013;12(7):809–19. doi:10.1586/14760584.2013.811208.
   PubMed Web of Science ®Google Scholar
• Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Sci. 2004;303:1529–31. doi:10.1126/science.1093616.
   PubMed Web of Science ®Google Scholar
• Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, Horiuchi T, Tomizawa H, Takeda K, Akira S. et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88–dependent signaling pathway. Nat Immunol. 2002;3(2):196–200. doi:10.1038/ni758.
   PubMed Web of Science ®Google Scholar
• Lund JM, Alexopoulou L, Sato A, Karow M, Adams NC, Gale NW, Iwasaki A, Flavell RA. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci. 2004;101(15):5598–603. doi:10.1073/pnas.0400937101.
   PubMed Web of Science ®Google Scholar
• Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, Lipford G, Wagner H, Bauer S. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Sci. 2004;303(5663):1526–9. doi:10.1126/science.1093620.
   PubMed Web of Science ®Google Scholar
• Blasius AL, Beutler B. Intracellular toll-like receptors. Immunity. 2010;32(3):305–15. doi:10.1016/j.immuni.2010.03.012.
   PubMed Web of Science ®Google Scholar
• Jurk M, Heil F, Vollmer J, Schetter C, Krieg AM, Wagner H, Lipford G, Bauer S. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat Immunol. 2002;3(6):499. doi:10.1038/ni0602-499.
   PubMed Web of Science ®Google Scholar
• Bhagchandani S, Johnson JA, Irvine DJ. Evolution of Toll-like receptor 7/8 agonist therapeutics and their delivery approaches: from antiviral formulations to vaccine adjuvants. Adv Drug Deliv Rev. 2021;175:113803. doi:10.1016/j.addr.2021.05.013.
   PubMed Web of Science ®Google Scholar
• Philbin VJ, Dowling DJ, Gallington LC, Cortés G, Tan Z, Suter EE, Chi KW, Shuckett A, Stoler-Barak L, Tomai M. et al. Imidazoquinoline Toll-like receptor 8 agonists activate human newborn monocytes and dendritic cells through adenosine-refractory and caspase-1–dependent pathways. J Allergy Clin Immunol. 2012;130(1):195–204. e9 doi:10.1016/j.jaci.2012.02.042.
   PubMed Web of Science ®Google Scholar
• Levy O, Suter EE, Miller RL, Wessels MR. Unique efficacy of Toll-like receptor 8 agonists in activating human neonatal antigen-presenting cells. Blood. 2006;108(4):1284–90. doi:10.1182/blood-2005-12-4821.
   PubMed Web of Science ®Google Scholar
• Levy O, Zarember KA, Roy RM, Cywes C, Godowski PJ, Wessels MR. Selective impairment of TLR-mediated innate immunity in human newborns: neonatal blood plasma reduces monocyte TNF-α induction by bacterial lipopeptides, lipopolysaccharide, and Imiquimod, but preserves the response to R-848. J Immunol. 2004;173(7):4627–34. doi:10.4049/jimmunol.173.7.4627.
   PubMed Web of Science ®Google Scholar
• Kaushik D, Kaur A, Petrovsky N, Salunke DB. Structural evolution of toll-like receptor 7/8 agonists from imidazoquinolines to imidazoles. RSC Med Chem. 2021;12(7):1065–120. doi:10.1039/D1MD00031D.
   PubMedGoogle Scholar
• Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K. et al. A Toll-like receptor recognizes bacterial DNA. Nature. 2000;408(6813):740–5. doi:10.1038/35047123.
   PubMed Web of Science ®Google Scholar
• Kumagai Y, Takeuchi O, Akira S. TLR9 as a key receptor for the recognition of DNA. Adv Drug Deliv Rev. 2008;60(7):795–804. doi:10.1016/j.addr.2007.12.004.
   PubMed Web of Science ®Google Scholar
• Babenko VN, Chadaeva IV, Orlov YL. Genomic landscape of CpG rich elements in human. BMC Evol Biol. 2017;17:19. doi:10.1186/s12862-016-0864-0.
   PubMed Web of Science ®Google Scholar
• Wagner H. The sweetness of the DNA backbone drives Toll-like receptor 9. Curr Opin Immunol. 2008;20(4):396–400. doi:10.1016/j.coi.2008.06.013.
   PubMed Web of Science ®Google Scholar
• Coch C, Busch N, Wimmenauer V, Hartmann E, Janke M, Abdel-Mottaleb MM, Lamprecht A, Ludwig J, Barchet W, Schlee M. et al. Higher activation of TLR9 in plasmacytoid dendritic cells by microbial DNA compared with self-DNA based on CpG-specific recognition of phosphodiester DNA. J Leukoc Biol. 2009;86(3):663–70. doi:10.1189/jlb.0509314.
   PubMed Web of Science ®Google Scholar
• Lamphier MS, Sirois CM, Verma A, Golenbock DT, Latz E. TLR9 and the recognition of self and non-self nucleic acids. Ann N Y Acad Sci. 2006;1082(1):31–43. doi:10.1196/annals.1348.005.
   PubMedGoogle Scholar
• Casanova JL, Abel L, Quintana-Murci L. Human TLRs and IL-1Rs in host defense: natural insights from evolutionary, epidemiological, and clinical genetics. Annu Rev Immunol. 2011;29(1):447–91. doi:10.1146/annurev-immunol-030409-101335.
   PubMedGoogle Scholar
• Schneberger D, Caldwell S, Kanthan R, Singh B. Expression of Toll-like receptor 9 in mouse and human lungs. J Anat. 2013;222(5):495–503. doi:10.1111/joa.12039.
   PubMed Web of Science ®Google Scholar
• Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2010;11(5):373–84. doi:10.1038/ni.1863.
   PubMed Web of Science ®Google Scholar
• Guiducci C, Ott G, Chan JH, Damon E, Calacsan C, Matray T, Lee K-D, Coffman RL, Barrat FJ. Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation. J Exp Med. 2006;203(8):1999–2008. doi:10.1084/jem.20060401.
   PubMed Web of Science ®Google Scholar
• Vollmer J, Weeratna R, Payette P, Jurk M, Schetter C, Laucht M, Wader T, Tluk S, Liu M, Davis H. et al. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol. 2004;34(1):251–62. doi:10.1002/eji.200324032.
   PubMed Web of Science ®Google Scholar
• Jiang W, Lederman MM, Harding CV, Rodriguez B, Mohner RJ, Sieg SF. TLR9 stimulation drives naïve B cells to proliferate and to attain enhanced antigen presenting function. Eur J Immunol. 2007;37(8):2205–13. doi:10.1002/eji.200636984.
   PubMed Web of Science ®Google Scholar
• Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov. 2006;5(6):471–84. doi:10.1038/nrd2059.
   PubMed Web of Science ®Google Scholar
• Donhauser N, Helm M, Pritschet K, Schuster P, Ries M, Korn K, Vollmer J, Schmidt B. Differential effects of P-class versus other CpG oligodeoxynucleotide classes on the impaired innate immunity of plasmacytoid dendritic cells in HIV type 1 infection. AIDS Res Hum Retroviruses. 2010;26(2):161–71. doi:10.1089/aid.2008.0278.
   PubMed Web of Science ®Google Scholar
• Wittig B, Schmidt M, Scheithauer W, Schmoll HJ. MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: from bench to bedside. Crit Rev Oncol Hematol. 2015;94(1):31–44. doi:10.1016/j.critrevonc.2014.12.002.
   PubMed Web of Science ®Google Scholar
• Holtick U, Scheulen ME, von Bergwelt-Baildon MS, Weihrauch MR. Toll-like receptor 9 agonists as cancer therapeutics. Expert Opin Investig Drugs. 2011;20(3):361–72. doi:10.1517/13543784.2011.553187.
   PubMed Web of Science ®Google Scholar
• Yu D, Putta MR, Bhagat L, Dai M, Wang D, Trombino AF, Sullivan T, Kandimalla ER, Agrawal S. Impact of secondary structure of toll-like receptor 9 agonists on interferon alpha induction. Antimicrob Agents Chemother. 2008;52(12):4320–5. doi:10.1128/AAC.00701-08.
   PubMed Web of Science ®Google Scholar
• Agrawal S, Kandimalla ER. Synthetic agonists of Toll-like receptors 7, 8 and 9. Biochem Soc Trans. 2007;35(6):1461–7. doi:10.1042/BST0351461.
   PubMedGoogle Scholar
• Wang D, Zhu F, DiMuzio J, Agrawal S. Abstract B196: intratumoral administration of IMO-2125, a novel TLR9 agonist, modulates tumor microenvironment and potentiates antitumor activity of anti-PD-1 mAb in a murine colon carcinoma model. Mol Cancer Ther. 2015;14(12_Supplement_2):B196–B. doi:10.1158/1535-7163.TARG-15-B196.
   Google Scholar
• Schmidt M, Hagner N, Marco A, König-Merediz SA, Schroff M, Wittig B. Design and structural requirements of the potent and safe TLR-9 agonistic immunomodulator MGN1703. Nucleic Acid Ther. 2015;25(3):130–40. doi:10.1089/nat.2015.0533.
   PubMed Web of Science ®Google Scholar
• Chuang TH, Ulevitch RJ. Identification of hTLR10: a novel human Toll-like receptor preferentially expressed in immune cells. Biochimica Et Biophysica Acta (BBA) - Gene Struct And Expression. 2001;1518(1–2):157–61. doi:10.1016/S0167-4781(00)00289-X.
   PubMedGoogle Scholar
• Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdörfer B, Giese T, Endres S, Hartmann G. Quantitative expression of toll-like receptor 1–10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG Oligodeoxynucleotides. J Immunol. 2002;168(9):4531–7. doi:10.4049/jimmunol.168.9.4531.
   PubMed Web of Science ®Google Scholar
• Govindaraj RG, Manavalan B, Lee G, Choi S, Selvarajoo K. Molecular modeling-based evaluation of hTLR10 and identification of potential ligands in Toll-like receptor signaling. PLOS ONE. 2010;5(9):e12713. doi:10.1371/journal.pone.0012713.
   PubMed Web of Science ®Google Scholar
• Sindhu S, Akhter N, Kochumon S, Thomas R, Wilson A, Shenouda S, Tuomilehto J, Ahmad R. Increased expression of the innate immune receptor TLR10 in obesity and type-2 diabetes: association with ROS-mediated oxidative stress. Cell Physiol Biochem. 2018;45(2):572–90. doi:10.1159/000487034.
   PubMedGoogle Scholar
• Oosting M, Cheng SC, Bolscher JM, Vestering-Stenger R, Plantinga TS, Verschueren IC, Arts P, Garritsen A, van Eenennaam H, Sturm P. et al. Human TLR10 is an anti-inflammatory pattern-recognition receptor. Proc Natl Acad Sci. 2014;111(42):E4478–E84. doi:10.1073/pnas.1410293111.
   PubMed Web of Science ®Google Scholar
• Lauw FN, Caffrey DR, Golenbock DT. Of mice and man: TLR11 (finally) finds profilin. Trends Immunol. 2005;26(10):509–11. doi:10.1016/j.it.2005.08.006.
   PubMed Web of Science ®Google Scholar
• Koblansky AA, Jankovic D, Oh H, Hieny S, Sungnak W, Mathur R, Hayden M, Akira S, Sher A, Ghosh S. et al. Recognition of profilin by Toll-like receptor 12 is critical for host resistance to Toxoplasma gondii. Immunity. 2013;38(1):119–30. doi:10.1016/j.immuni.2012.09.016.
   PubMed Web of Science ®Google Scholar
• Shi Z, Cai Z, Sanchez A, Zhang T, Wen S, Wang J, Yang J, Fu S, Zhang D. A novel Toll-like receptor that recognizes vesicular stomatitis virus. J Biol Chem. 2011;286(6):4517–24. doi:10.1074/jbc.M110.159590.
   PubMed Web of Science ®Google Scholar
• Raetz M, Kibardin A, Sturge CR, Pifer R, Li H, Burstein E, Ozato K, Larin S, Yarovinsky F. Cooperation of TLR12 and TLR11 in the IRF8-dependent IL-12 response to Toxoplasma gondii profilin. J Immunol. 2013;191(9):4818–27. doi:10.4049/jimmunol.1301301.
   PubMed Web of Science ®Google Scholar
• Hatai H, Lepelley A, Zeng W, Hayden MS, Ghosh S, Blader IJ. Toll-like receptor 11 (TLR11) interacts with Flagellin and profilin through disparate mechanisms. PLoS ONE. 2016;11(2):e0148987. doi:10.1371/journal.pone.0148987.
   PubMed Web of Science ®Google Scholar
• Hochrein H, Kirschning CJ. Bacteria evade immune recognition via TLR13 and binding of their 23S rRNA by MLS antibiotics by the same mechanisms. Oncoimmunology. 2013;2(3):e23141. doi:10.4161/onci.23141.
   PubMed Web of Science ®Google Scholar
• Yarovinsky F, Hieny S, Sher A. Recognition of Toxoplasma gondii by TLR11 prevents parasite-induced immunopathology. J Immunol. 2008;181(12):8478–84. doi:10.4049/jimmunol.181.12.8478.
   PubMed Web of Science ®Google Scholar
• Hidmark A, von Saint Paul A, Dalpke AH. Cutting edge: TLR13 is a receptor for bacterial RNA. J Immunol. 2012;189(6):2717–21. doi:10.4049/jimmunol.1200898.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Luo F, Li A, Qian J, Yao Z, Feng X, Chu Y. Systemic injection of TLR1/2 agonist improves adoptive antigen-specific T cell therapy in glioma-bearing mice. Clin Immunol. 2014;154(1):26–36. doi:10.1016/j.clim.2014.06.004.
   PubMed Web of Science ®Google Scholar
• Zahm CD, Colluru VT, McIlwain SJ, Ong IM, McNeel DG. TLR stimulation during T-cell activation lowers PD-1 expression on CD8(+) T cells. Cancer Immunol Res. 2018;6(11):1364–74. doi:10.1158/2326-6066.CIR-18-0243.
   PubMed Web of Science ®Google Scholar
• Renaudet O, Dasgupta G, Bettahi I, Shi A, Nesburn AB, Dumy P, BenMohamed L. Linear and branched Glyco-Lipopeptide vaccines follow distinct cross-presentation pathways and generate different magnitudes of antitumor immunity. PLOS ONE. 2010;5(6):e11216. doi:10.1371/journal.pone.0011216.
   PubMed Web of Science ®Google Scholar
• Shi W, Tong Z, Chen S, Qiu Q, Zhou J, Qian H. Development of novel self-assembled vaccines based on tumour-specific antigenic peptide and TLR2 agonist for effective breast cancer immunotherapy via activating CD8+ T cells and enhancing their function. Immunology. 2023;169(4):454–66. doi:10.1111/imm.13643.
   PubMed Web of Science ®Google Scholar
• Adams M, Navabi H, Jasani B, Man S, Fiander A, Evans AS, Donninger C, Mason M. Dendritic cell (DC) based therapy for cervical cancer: use of DC pulsed with tumour lysate and matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly [I]: poly [C12U] (Ampligen®). Vaccine. 2003;21(7–8):787–90. doi:10.1016/S0264-410X(02)00599-6.
   PubMed Web of Science ®Google Scholar
• Zhu X, Nishimura F, Sasaki K, Fujita M, Dusak JE, Eguchi J, Fellows-Mayle W, Storkus WJ, Walker PR, Salazar AM. et al. Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models. J Transl Med. 2007;5(1):10. doi:10.1186/1479-5876-5-10.
   PubMedGoogle Scholar
• Takeda Y, Yoshida S, Takashima K, Ishii-Mugikura N, Shime H, Seya T, Matsumoto M. Vaccine immunotherapy with ARNAX induces tumor-specific memory T cells and durable anti-tumor immunity in mouse models. Cancer Sci. 2018;109(7):2119–29. doi:10.1111/cas.13649.
   PubMed Web of Science ®Google Scholar
• Song H, Huang P, Niu J, Shi G, Zhang C, Kong D, Wang W. Injectable polypeptide hydrogel for dual-delivery of antigen and TLR3 agonist to modulate dendritic cells in vivo and enhance potent cytotoxic T-lymphocyte response against melanoma. Biomaterials. 2018;159:119–29. doi:10.1016/j.biomaterials.2018.01.004.
   PubMed Web of Science ®Google Scholar
• Wang C, Zhuang Y, Zhang Y, Luo Z, Gao N, Li P, Pan H, Cai L, Ma Y. Toll-like receptor 3 agonist complexed with cationic liposome augments vaccine-elicited antitumor immunity by enhancing TLR3–IRF3 signaling and type I interferons in dendritic cells. Vaccine. 2012;30(32):4790–9. doi:10.1016/j.vaccine.2012.05.027.
   PubMed Web of Science ®Google Scholar
• Vindevogel E, Baert T, Hoylandt AV, Verbist G, Velde GV, Garg AD, Agostinis P, Vergote I, Coosemans AN. The use of toll-like receptor 4 agonist to reshape the immune signature in ovarian cancer. Anticancer Res. 2016;36(11):5781–92. doi:10.21873/anticanres.11162.
   PubMed Web of Science ®Google Scholar
• Davis MB, Vasquez-Dunddel D, Fu J, Albesiano E, Pardoll D, Kim YJ. Intratumoral administration of TLR4 agonist absorbed into a cellular vector improves antitumor responses. Clin Cancer Res. 2011;17(12):3984–92. doi:10.1158/1078-0432.CCR-10-3262.
   PubMed Web of Science ®Google Scholar
• Shi HS, Gong CY, Zhang Hl, Wang YS, Zhang J, Luo ZC, Qian ZY, Wei YQ, Yang L. Novel vaccine adjuvant LPS-Hydrogel for truncated basic fibroblast growth factor to induce antitumor immunity. Carbohyd Polym. 2012;89(4):1101–9. doi:10.1016/j.carbpol.2012.03.073.
   PubMed Web of Science ®Google Scholar
• Hamdy S, Molavi O, Ma Z, Haddadi A, Alshamsan A, Gobti Z, Elhasi S, Samuel J, Lavasanifar A. Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity. Vaccine. 2008;26(39):5046–57. doi:10.1016/j.vaccine.2008.07.035.
   PubMed Web of Science ®Google Scholar
• Cheng R, Fontana F, Xiao J, Liu Z, Figueiredo P, Shahbazi MA, Wang S, Jin J, Torrieri G, Hirvonen JT. et al. Recombination monophosphoryl lipid A-derived vacosome for the development of preventive cancer vaccines. ACS Appl Mater Interfaces. 2020;12(40):44554–62. doi:10.1021/acsami.0c15057.
   PubMed Web of Science ®Google Scholar
• Bubna AK. Imiquimod - Its role in the treatment of cutaneous malignancies. Indian J Pharmacol. 2015;47(4):354–9. doi:10.4103/0253-7613.161249.
   PubMed Web of Science ®Google Scholar
• Ma F, Zhang J, Zhang J, Zhang C. The TLR7 agonists imiquimod and gardiquimod improve DC-based immunotherapy for melanoma in mice. Cell Mol Immunol. 2010;7(5):381–8. doi:10.1038/cmi.2010.30.
   PubMed Web of Science ®Google Scholar
• Stickdorn J, Stein L, Arnold-Schild D, Hahlbrock J, Medina-Montano C, Bartneck J, Ziß T, Montermann E, Kappel C, Hobernik D. et al. Systemically administered TLR7/8 agonist and antigen-conjugated nanogels govern immune responses against tumors. Acs Nano. 2022;16(3):4426–43. doi:10.1021/acsnano.1c10709.
   PubMed Web of Science ®Google Scholar
• Chi H, Hao Y, Wang X, Tang L, Deng Y, Chen X, Gao F, Sha O, Jin G. A therapeutic whole-tumor-cell vaccine covalently conjugated with a TLR7 agonist. Cells. 2022;11(13):1986. doi:10.3390/cells11131986.
   PubMed Web of Science ®Google Scholar
• Song H, Su Q, Shi W, Huang P, Zhang C, Zhang C, Zhang C, Liu Q, Wang W. Antigen epitope-TLR7/8a conjugate as self-assembled carrier-free nanovaccine for personalized immunotherapy. Acta Biomater. 2022;141:398–407. doi:10.1016/j.actbio.2022.01.004.
   PubMed Web of Science ®Google Scholar
• Lynn GM, Sedlik C, Baharom F, Zhu Y, Ramirez-Valdez RA, Coble VL, Tobin K, Nichols SR, Itzkowitz Y, Zaidi N. et al. Peptide–TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens. Nat Biotechnol. 2020;38(3):320–32. doi:10.1038/s41587-019-0390-x.
   PubMed Web of Science ®Google Scholar
• Kim SK, Ragupathi G, Musselli C, Choi SJ, Park YS, Livingston PO. Comparison of the effect of different immunological adjuvants on the antibody and T-cell response to immunization with MUC1-KLH and GD3-KLH conjugate cancer vaccines. Vaccine. 1999;18(7–8):597–603. doi:10.1016/S0264-410X(99)00316-3.
   PubMed Web of Science ®Google Scholar
• Sin JI, Kim H, Ahn E, Jeon YH, Park WS, Lee S-Y, Kwon B. Combined stimulation of TLR9 and 4.1BB augments Trp2 peptide vaccine-mediated melanoma rejection by increasing Ag-specific CTL activity and infiltration into tumor sites. Cancer Lett. 2013;330(2):190–9. doi:10.1016/j.canlet.2012.11.045.
   PubMed Web of Science ®Google Scholar
• Shi X, Song H, Wang C, Zhang C, Huang P, Kong D, Zhang J, Wang W. Co-assembled and self-delivered epitope/CpG nanocomplex vaccine augments peptide immunogenicity for cancer immunotherapy. Chem Eng J. 2020;399:125854. doi:10.1016/j.cej.2020.125854.
   Web of Science ®Google Scholar
• Chen T, Liu K, Xu J, Zhan T, Liu M, Li L, Yang Z, Yuan S, Zou W, Lin G. et al. Synthetic and immunological studies on the OCT4 immunodominant motif antigen-based anti-cancer vaccine. Cancer Biol Med. 2020;17(1):132–41. doi:10.20892/j.issn.2095-3941.2019.0224.
   PubMed Web of Science ®Google Scholar
• Zaks K, Jordan M, Guth A, Sellins K, Kedl R, Izzo A, Bosio C, Dow S. Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic Liposomes1. J Immunol. 2006;176(12):7335–45. doi:10.4049/jimmunol.176.12.7335.
   PubMed Web of Science ®Google Scholar
• Jeon D, McNeel DG. Toll-like receptor agonist combinations augment mouse T-cell anti-tumor immunity via IL-12- and interferon ß-mediated suppression of immune checkpoint receptor expression. Oncoimmunology. 2022;11(1):2054758. doi:10.1080/2162402X.2022.2054758.
   PubMed Web of Science ®Google Scholar
• Prins RM, Soto H, Konkankit V, Odesa SK, Eskin A, Yong WH, Nelson SF, Liau LM. Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res. 2011;17(6):1603–15. doi:10.1158/1078-0432.CCR-10-2563.
   PubMed Web of Science ®Google Scholar
• Tsuji T, Sabbatini P, Jungbluth AA, Ritter E, Pan L, Ritter G, Ferran L, Spriggs D, Salazar AM, Gnjatic S. et al. Effect of Montanide and poly-ICLC adjuvant on human self/tumor antigen-specific CD4+ T cells in phase I overlapping long peptide vaccine trial. Cancer Immunol Res. 2013;1(5):340–50. doi:10.1158/2326-6066.CIR-13-0089.
   PubMed Web of Science ®Google Scholar
• Pavlick A, Blazquez AB, Meseck M, Lattanzi M, Ott PA, Marron TU, Holman RM, Mandeli J, Salazar AM, McClain CB. et al. Combined vaccination with NY-ESO-1 protein, poly-ICLC, and montanide improves humoral and cellular immune responses in patients with high-risk melanoma. Cancer Immunol Res. 2020;8(1):70–80. doi:10.1158/2326-6066.CIR-19-0545.
   PubMed Web of Science ®Google Scholar
• Dillon PM, Petroni GR, Smolkin ME, Brenin DR, Chianese-Bullock KA, Smith KT, Olson WC, Fanous IS, Nail CJ, Brenin CM. et al. A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancer. J Immunother Cancer. 2017;5(1):92. doi:10.1186/s40425-017-0295-5.
   PubMedGoogle Scholar
• Melssen MM, Petroni GR, Chianese-Bullock KA, Wages NA, Grosh WW, Varhegyi N, Smolkin ME, Smith KT, Galeassi NV, Deacon DH. et al. A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund’s adjuvant in melanoma patients. J Immunother Cancer. 2019;7(1):163. doi:10.1186/s40425-019-0625-x.
   PubMed Web of Science ®Google Scholar
• Mahipal A, Odunsi K, Gnjatic S, Kim-Schulze S, Kenney RT, Ejadi S. A first-in-human phase 1 dose-escalating trial of G305 in patients with solid tumors expressing NY-ESO-1. J Clin Oncol. 2015;33(15_suppl):3073–. doi:10.1200/jco.2015.33.15_suppl.3073.
   Google Scholar
• Neidhart J, Allen KO, Barlow DL, Carpenter M, Shaw DR, Triozzi PL, Conry RM. Immunization of colorectal cancer patients with recombinant baculovirus-derived KSA (Ep-CAM) formulated with monophosphoryl lipid a in liposomal emulsion, with and without granulocyte-macrophage colony-stimulating factor. Vaccine. 2004;22(5–6):773–80. doi:10.1016/j.vaccine.2003.08.021.
   PubMed Web of Science ®Google Scholar
• Grewal EP, Erskine CL, Nevala WK, Allred JB, Strand CA, Kottschade LA, McWilliams RR, Dronca RS, Yakovich AJ, Markovic SN. et al. Peptide vaccine with glucopyranosyl lipid A–stable oil-in-water emulsion for patients with resected melanoma. Immunotherapy. 2020;12(13):983–95. doi:10.2217/imt-2020-0085.
   PubMed Web of Science ®Google Scholar
• Shackleton M, Davis ID, Hopkins W, Jackson H, Dimopoulos N, Tai T, Chen Q, Parente P, Jefford M, Masterman KA. et al. The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand. Cancer Immun. 2004;4:9.
   PubMedGoogle Scholar
• Adams S, O’Neill DW, Nonaka D, Hardin E, Chiriboga L, Siu K, Cruz CM, Angiulli A, Angiulli F, Ritter E. et al. Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J Immunol. 2008;181(1):776–84. doi:10.4049/jimmunol.181.1.776.
   PubMed Web of Science ®Google Scholar
• Mauldin IS, Wages NA, Stowman AM, Wang E, Smolkin ME, Olson WC, Deacon DH, Smith KT, Galeassi N, Teague JE. et al. Pilot clinical trials testing the safety and effects on the metastatic melanoma microenvironment of intratumoral interferon-gamma or imiquimod, plus a multipeptide melanoma vaccine. J Immuno Ther Cancer. 2015;3:139. doi:10.1186/2051-1426-3-S2-P139.
   Google Scholar
• Sabado RL, Pavlick AC, Gnjatic S, Cruz CM, Vengco I, Hasan F, Darvishian F, Chiriboga L, Holman RM, Escalon J. et al. Phase I/II study of resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with melanoma. J Clin Oncol. 2014;32:9086–. doi:10.1200/jco.2014.32.15_suppl.9086.
   Web of Science ®Google Scholar
• Royal RE, Vence LM, Wray T, Cormier JN, Lee JE, Gershenwald JE, Ross MI, Wargo JA, Amaria RN, Davies MA. et al. A toll-like receptor agonist to drive melanoma regression as a vaccination adjuvant or by direct tumor application. J Clin Oncol. 2017;35:9582–. doi:10.1200/JCO.2017.35.15_suppl.9582.
   Web of Science ®Google Scholar
• Speiser DE, Liénard D, Rufer N, Rubio-Godoy V, Rimoldi D, Lejeune F, Krieg AM, Cerottini J-C, Romero P. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest. 2005;115(3):739–46. doi:10.1172/JCI23373.
   PubMed Web of Science ®Google Scholar
• Iwahashi M, Katsuda M, Nakamori M, Nakamura M, Naka T, Ojima T, Iida T, Yamaue H. Vaccination with peptides derived from cancer-testis antigens in combination with CpG-7909 elicits strong specific CD8+ T cell response in patients with metastatic esophageal squamous cell carcinoma. Cancer Sci. 2010;101(12):2510–7. doi:10.1111/j.1349-7006.2010.01732.x.
   PubMed Web of Science ®Google Scholar
• Mahipal A, Ejadi S, Gnjatic S, Kim-Schulze S, Lu H, Ter Meulen JH, Kenney R, Odunsi K. First-in-human phase 1 dose-escalating trial of G305 in patients with advanced solid tumors expressing NY-ESO-1. Cancer Immunol Immunother. 2019;68(7):1211–22. doi:10.1007/s00262-019-02331-x.
   PubMed Web of Science ®Google Scholar
• Sabado RL, Pavlick A, Gnjatic S, Cruz CM, Vengco I, Hasan F, Spadaccia M, Darvishian F, Chiriboga L, Holman RM. et al. Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma. Cancer Immunol Res. 2015;3(3):278–87. doi:10.1158/2326-6066.CIR-14-0202.
   PubMed Web of Science ®Google Scholar
• Sabbatini P, Tsuji T, Ferran L, Ritter E, Sedrak C, Tuballes K, Jungbluth AA, Ritter G, Aghajanian C, Bell-McGuinn K. et al. Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clin Cancer Res. 2012;18(23):6497–508. doi:10.1158/1078-0432.CCR-12-2189.
   PubMed Web of Science ®Google Scholar
• Mauldin IS, Wages NA, Stowman AM, Wang E, Olson WC, Deacon DH, Smith KT, Galeassi N, Teague JE, Smolkin ME. et al. Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases. Cancer Immunol Immunother. 2016;65(10):1201–12. doi:10.1007/s00262-016-1880-z.
   PubMed Web of Science ®Google Scholar
• Noguchi M, Arai G, Egawa S, Ohyama C, Naito S, Matsumoto K, Uemura H, Nakagawa M, Nasu Y, Eto M. et al. Mixed 20-peptide cancer vaccine in combination with docetaxel and dexamethasone for castration-resistant prostate cancer: a randomized phase II trial. Cancer Immunol Immunother. 2020;69(5):847–57. doi:10.1007/s00262-020-02498-8.
   PubMed Web of Science ®Google Scholar
• Clifton GT, Peoples GE, Mittendorf EA. The development and use of the E75 (HER2 369–377) peptide vaccine. Future Oncol. 2016;12(11):1321–9. doi:10.2217/fon-2015-0054.
   PubMed Web of Science ®Google Scholar
• Carvalho T. Personalized anti-cancer vaccine combining mRNA and immunotherapy tested in melanoma trial. Nat Med. 2023;29(10):2379–2380. doi:10.1038/d41591-023-00072-0.
   PubMed Web of Science ®Google Scholar
• Pascolo S. Vaccination with messenger RNA. Methods Mol Med. 2006;127:23–40.
   PubMedGoogle Scholar